The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 342:374-380 February 10, 2000 Number 6
NextNext

Prothrombin and Factor V Mutations in Women with a History of Thrombosis during Pregnancy and the Puerperium
Andrea Gerhardt, M.D., Rüdiger Eberhard Scharf, M.D., Matthias Wilhelm Beckmann, M.D., Sabine Struve, B.S., Hans Georg Bender, M.D., Michael Pillny, M.D., Wilhelm Sandmann, M.D., and Rainer Bernd Zotz, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
 by Greer, I. A.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Venous thromboembolism is a leading cause of morbidity and mortality during pregnancy and the puerperium. However, the role of mutations in the prothrombin and factor V genes and other thrombophilic abnormalities as risk factors for thromboembolism in women during pregnancy and the puerperium is not known.

Methods In a study of 119 women with a history of venous thromboembolism during pregnancy and the puerperium and 233 age-matched normal women, we measured the activity of antithrombin, protein C, protein S, and lupus anticoagulant. We also performed genetic analyses to detect the G1691A mutation in the factor V gene (factor V Leiden), the G20210A mutation in the prothrombin gene, and the C677T mutation in the methylenetetrahydrofolate reductase gene. Blood samples were obtained at least three months post partum or after the cessation of lactation.

Results Among the women with a history of venous thromboembolism, the prevalence of factor V Leiden was 43.7 percent, as compared with 7.7 percent among the normal women (relative risk of venous thromboembolism, 9.3; 95 percent confidence interval, 5.1 to 16.9); that of the G20210A prothrombin-gene mutation, 16.9 percent as compared with 1.3 percent (relative risk, 15.2; 95 percent confidence interval, 4.2 to 52.6); and that of both factor V Leiden and the G20210A prothrombin-gene mutation, 9.3 percent as compared with 0 (estimated odds ratio, 107). Assuming an overall risk of 1 in 1500 pregnancies, the risk of thrombosis among carriers of factor V Leiden was 0.2 percent, among carriers of the G20210A prothrombin-gene mutation, 0.5 percent, and among carriers of both defects, 4.6 percent, as calculated in a multivariate analysis.

Conclusions The G20210A prothrombin-gene mutation and factor V Leiden individually are associated with an increased risk of venous thromboembolism during pregnancy and the puerperium, and the risk among women with both mutations is disproportionately higher than that among women with only one mutation.


Source Information

From the Departments of Hemostasis and Transfusion Medicine (A.G., R.E.S., R.B.Z.), Obstetrics and Gynecology (M.W.B., S.S., H.G.B.), and Vascular Surgery and Kidney Transplantation (M.P., W.S.), Heinrich Heine University Medical Center, Düsseldorf, Germany.

Address reprint requests to Dr. Zotz at the Institut für Haemostaseologie und Transfusionsmedizin, Heinrich Heine Universität, Moorenstr. 5, D-40225 Düsseldorf, Germany, or at zotz{at}med.uni-duesseldorf.de.

Full Text of this Article


Related Letters:

Prothrombin and Factor V Mutations in Women with a History of Thrombosis during Pregnancy and the Puerperium
Moll S., Escobar M., Zotz R. B., Gerhardt A., Scharf R. E.
Extract | Full Text  
N Engl J Med 2000; 342:1996-1997, Jun 29, 2000. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.